Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer

This study tests whether adding homoharringtonine (HHT), a plant-derived chemotherapy agent, to standard hormone-blocking therapy (androgen deprivation therapy) before surgery helps shrink prostate cancer tumors more effectively — a treatment approach called neoadjuvant therapy. **You may be eligible if...** - You are between 18 and 85 years old - You have prostate cancer confirmed by biopsy (not the small cell type) - Your cancer has spread to a small number of sites (up to 5 metastases in bone or lymph nodes) or is locally advanced (stage T3–T4) - You have a good performance status (ECOG 0 or 1) - You have not received any previous prostate cancer treatment **You may NOT be eligible if...** - You have had any prior prostate cancer treatment (radiation, hormone therapy, chemotherapy) - You have already had prostate surgery - You are allergic to any of the study drugs - You have serious other medical or mental health conditions that could affect treatment Talk to your doctor to see if this trial is right for you.